Acasti Pharma PE Ratio 2014-2024 | GRCE
Current and historical p/e ratio for Acasti Pharma (GRCE) from 2014 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Acasti Pharma PE ratio as of October 29, 2024 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Acasti Pharma PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-10-28 |
3.21 |
|
0.00 |
| 2024-06-30 |
2.92 |
$-1.14 |
0.00 |
| 2024-03-31 |
3.43 |
$-1.44 |
0.00 |
| 2023-12-31 |
2.89 |
$-5.08 |
0.00 |
| 2023-09-30 |
2.78 |
$-5.41 |
0.00 |
| 2023-06-30 |
3.15 |
$-5.64 |
0.00 |
| 2023-03-31 |
2.76 |
$-5.70 |
0.00 |
| 2022-12-31 |
3.01 |
$-2.04 |
0.00 |
| 2022-09-30 |
3.50 |
$-2.04 |
0.00 |
| 2022-06-30 |
5.15 |
$-1.20 |
0.00 |
| 2022-03-31 |
7.32 |
$-1.08 |
0.00 |
| 2021-12-31 |
7.56 |
$-2.28 |
0.00 |
| 2021-09-30 |
12.00 |
$-2.70 |
0.00 |
| 2021-06-30 |
26.95 |
$-5.28 |
0.00 |
| 2021-03-31 |
28.80 |
$-7.20 |
0.00 |
| 2020-12-31 |
15.60 |
$0.48 |
32.50 |
| 2020-09-30 |
9.61 |
$-5.28 |
0.00 |
| 2020-06-30 |
22.52 |
$-15.36 |
0.00 |
| 2020-03-31 |
18.22 |
$-18.24 |
0.00 |
| 2019-12-31 |
117.60 |
$-32.63 |
0.00 |
| 2019-09-30 |
90.72 |
$-28.31 |
0.00 |
| 2019-06-30 |
54.72 |
$-38.39 |
0.00 |
| 2019-03-31 |
48.96 |
$-41.75 |
0.00 |
| 2018-12-31 |
39.93 |
$-79.66 |
0.00 |
| 2018-09-30 |
61.92 |
$-92.14 |
0.00 |
| 2018-06-30 |
27.36 |
$-81.58 |
0.00 |
| 2018-03-31 |
48.96 |
$-79.66 |
0.00 |
| 2017-12-31 |
45.25 |
$-33.59 |
0.00 |
| 2017-09-30 |
68.16 |
$-18.72 |
0.00 |
| 2017-06-30 |
63.36 |
$-6.72 |
0.00 |
| 2017-02-28 |
60.00 |
0 |
0.00 |
| 2016-11-30 |
67.20 |
$-6.24 |
0.00 |
| 2016-08-31 |
63.84 |
$-6.24 |
0.00 |
| 2016-05-31 |
72.00 |
$-13.92 |
0.00 |
| 2016-03-31 |
72.96 |
$-14.40 |
0.00 |
| 2016-02-29 |
72.00 |
$-12.96 |
0.00 |
| 2015-12-31 |
122.40 |
$-22.56 |
0.00 |
| 2015-09-30 |
129.07 |
$-0.48 |
0.00 |
| 2015-06-30 |
151.20 |
$-14.40 |
0.00 |
| 2015-03-31 |
230.16 |
$-4.80 |
0.00 |
| 2014-12-31 |
240.00 |
$-14.40 |
0.00 |
| 2014-09-30 |
369.60 |
$-43.19 |
0.00 |
| 2014-06-30 |
489.60 |
$-43.19 |
0.00 |
| 2013-09-30 |
1137.60 |
$-57.59 |
0.00 |
| 2013-06-30 |
1358.40 |
$-38.39 |
0.00 |
| 2013-03-31 |
1022.40 |
$-47.99 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
